<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><description>医药行业一致性评价工作在如火如荼的进行中，作为行业的一份子，愿本愚公之念，出蝼蚁 之力，献寸光之策。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 06 Apr 2021 23:22:59 +0800</pubDate><image><url>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</url><title>药春秋 | wechat-feeds</title><link>http://MzI0MDM2NTA4NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>吸入剂优质赛道，国产品牌迅速崛起，已是入场好时机？</title><link>https://mp.weixin.qq.com/s/FchgnCTVu-63spkYejfEYA</link><description></description><content:encoded><![CDATA[吸入剂优质赛道，国产品牌迅速崛起，已是入场好时机？]]></content:encoded><pubDate>Tue, 06 Apr 2021 21:37:43 +0800</pubDate></item><item><title>二甲双胍，传来新消息！</title><link>https://mp.weixin.qq.com/s/QpP5Dbus3kWiO8qToVbXKw</link><description></description><content:encoded><![CDATA[二甲双胍，传来新消息！]]></content:encoded><pubDate>Tue, 06 Apr 2021 21:37:43 +0800</pubDate></item><item><title>11品种纳入带量采购；量大、获批早等药品优势明显</title><link>https://mp.weixin.qq.com/s/ePvWU8mwRQV1udsLTz-njw</link><description></description><content:encoded><![CDATA[11品种纳入带量采购；量大、获批早等药品优势明显]]></content:encoded><pubDate>Tue, 06 Apr 2021 21:37:43 +0800</pubDate></item><item><title>涉及原料药垄断，知名药企再遭巨额罚款...</title><link>https://mp.weixin.qq.com/s/A9YwZo_yzK2QQbPBFEo8wg</link><description></description><content:encoded><![CDATA[涉及原料药垄断，知名药企再遭巨额罚款...]]></content:encoded><pubDate>Tue, 06 Apr 2021 21:37:43 +0800</pubDate></item><item><title>药品注册：从入门到放弃……</title><link>https://mp.weixin.qq.com/s/gnGh7tWaQV6OlG7lzPlHew</link><description></description><content:encoded><![CDATA[药品注册：从入门到放弃……]]></content:encoded><pubDate>Sat, 03 Apr 2021 21:36:32 +0800</pubDate></item><item><title>丽珠财报：17亿独家注射剂“疯涨”，助力集团净利提高31%</title><link>https://mp.weixin.qq.com/s/-ahdsEUdZIfhzRWmkcGc1g</link><description></description><content:encoded><![CDATA[丽珠财报：17亿独家注射剂“疯涨”，助力集团净利提高31%]]></content:encoded><pubDate>Fri, 02 Apr 2021 21:39:24 +0800</pubDate></item><item><title>吸入剂BE研究：国内外异同要点一览</title><link>https://mp.weixin.qq.com/s/fNUe4ktdqEr6KJVDEi_tBA</link><description></description><content:encoded><![CDATA[吸入剂BE研究：国内外异同要点一览]]></content:encoded><pubDate>Fri, 02 Apr 2021 21:39:24 +0800</pubDate></item><item><title>161个品种新增挂网</title><link>https://mp.weixin.qq.com/s/L1vCLbIkObFhL2Jvc8nzcQ</link><description></description><content:encoded><![CDATA[161个品种新增挂网]]></content:encoded><pubDate>Fri, 02 Apr 2021 21:39:24 +0800</pubDate></item><item><title>《药品上市后变更管理实施细则》公开征求意见</title><link>https://mp.weixin.qq.com/s/Wp14e5giK04gVy4moNrDSg</link><description></description><content:encoded><![CDATA[《药品上市后变更管理实施细则》公开征求意见]]></content:encoded><pubDate>Fri, 02 Apr 2021 21:39:24 +0800</pubDate></item><item><title>（2021.4.1）一致性评价目录：4品种首仿诞生，视同过评…</title><link>https://mp.weixin.qq.com/s/n2CdtWOCWfGOMVLg7491rw</link><description></description><content:encoded><![CDATA[（2021.4.1）一致性评价目录：4品种首仿诞生，视同过评…]]></content:encoded><pubDate>Thu, 01 Apr 2021 21:36:41 +0800</pubDate></item><item><title>124个药暂停采购</title><link>https://mp.weixin.qq.com/s/KvCze-JMn75mYR_kXnLHpg</link><description></description><content:encoded><![CDATA[124个药暂停采购]]></content:encoded><pubDate>Thu, 01 Apr 2021 21:36:41 +0800</pubDate></item><item><title>注意！八类药不适用于「长处方」</title><link>https://mp.weixin.qq.com/s/mntrywDMc8ngneeMa7jkEQ</link><description></description><content:encoded><![CDATA[注意！八类药不适用于「长处方」]]></content:encoded><pubDate>Thu, 01 Apr 2021 21:36:41 +0800</pubDate></item><item><title>药价常态化调整，提上日程！</title><link>https://mp.weixin.qq.com/s/i3f7d3W9oQg-fg9wPLdw_w</link><description></description><content:encoded><![CDATA[药价常态化调整，提上日程！]]></content:encoded><pubDate>Thu, 01 Apr 2021 21:36:41 +0800</pubDate></item><item><title>大热注射剂，最高过评20家，需适当“避雷”…</title><link>https://mp.weixin.qq.com/s/fQy09wc3dzo0YN6iQxhLVQ</link><description></description><content:encoded><![CDATA[大热注射剂，最高过评20家，需适当“避雷”…]]></content:encoded><pubDate>Wed, 31 Mar 2021 21:38:26 +0800</pubDate></item><item><title>达比加群酯：高难度抗凝剂，百亿市场下谁与争锋？</title><link>https://mp.weixin.qq.com/s/DYSnEd50LpPQ8bWARrPNYw</link><description></description><content:encoded><![CDATA[达比加群酯：高难度抗凝剂，百亿市场下谁与争锋？]]></content:encoded><pubDate>Wed, 31 Mar 2021 21:38:26 +0800</pubDate></item><item><title>价格异常，16个药品被重点关注！</title><link>https://mp.weixin.qq.com/s/sQ9DSIf-toMW7xosvzosew</link><description></description><content:encoded><![CDATA[价格异常，16个药品被重点关注！]]></content:encoded><pubDate>Wed, 31 Mar 2021 21:38:26 +0800</pubDate></item><item><title>药品专利期限补偿制度，创新药VS仿制药</title><link>https://mp.weixin.qq.com/s/odNxhevi3rzOpsya0PgWoA</link><description></description><content:encoded><![CDATA[药品专利期限补偿制度，创新药VS仿制药]]></content:encoded><pubDate>Wed, 31 Mar 2021 21:38:26 +0800</pubDate></item><item><title>最新过评动态：30亿大品种迎齐鲁、倍特、海灵同日冲线！</title><link>https://mp.weixin.qq.com/s/3IuBBrKJ3wOxFqmMGQCkPA</link><description></description><content:encoded><![CDATA[最新过评动态：30亿大品种迎齐鲁、倍特、海灵同日冲线！]]></content:encoded><pubDate>Tue, 30 Mar 2021 21:35:59 +0800</pubDate></item><item><title>医保局点名 - 69个药被重点监控、关注</title><link>https://mp.weixin.qq.com/s/rIQGVMoIqeqptcsdJ20EGQ</link><description></description><content:encoded><![CDATA[医保局点名 - 69个药被重点监控、关注]]></content:encoded><pubDate>Tue, 30 Mar 2021 21:35:59 +0800</pubDate></item><item><title>这些国采非中选药，机会来了！</title><link>https://mp.weixin.qq.com/s/TNIfvSl45hAxmuEgyiPKiw</link><description></description><content:encoded><![CDATA[这些国采非中选药，机会来了！]]></content:encoded><pubDate>Tue, 30 Mar 2021 21:35:59 +0800</pubDate></item></channel></rss>